Her-2 positivity was higher in GEJ cancers than GC (33.2 vs. 20.9%, p = 0.001), and higher in intestinal than in diffuse/mixed cancer (32.2 vs. 6.1%/20.4%, p = 0.001) [9,54,55,56,57,58]. The gene discussed is ERBB2; the disease is gastric cancer.